Insurance · Founded 2005 · www.starhealth.in · BSE 543412 · NSE STARHEALTH · ISIN INE575P01011
No Notes Added Yet
Business
Star Health and Allied Insurance Company Ltd. is a specialized health insurance provider in India. The company focuses exclusively on health, personal accident, and overseas travel insurance products. Its core business model involves underwriting various health insurance policies for individuals, families, and corporates. Star Health primarily generates revenue through collecting premiums from its policyholders and investing these premiums (investment income) before claims are paid out. It offers a wide range of products including medi-classic, star comprehensive, senior citizen red carpet, star cancer care, and various group health policies.
Revenue Mix
Star Health is almost entirely focused on health insurance, which forms the overwhelming majority of its gross written premiums. Within health insurance, it primarily caters to the retail segment (individuals and families), which is its largest contributor. It also has a significant presence in the group health insurance segment and offers personal accident and overseas travel insurance, though these are relatively smaller contributors to the overall premium mix. Its specialized focus means there are no distinct major non-health insurance segments.
Industry
The Indian insurance industry is undergoing rapid growth, driven by increasing awareness and disposable incomes. The health insurance segment is particularly competitive, with both public sector general insurers and private players (including standalone health insurers like Star Health) vying for market share. Star Health is a market leader in the retail health insurance segment in India, characterized by its specialized focus and extensive distribution network. It differentiates itself by offering a wide array of health-specific products and by focusing on in-house claims processing.
MOAT
Star Health possesses several durable advantages:
Specialization & Brand Recognition: Its singular focus on health insurance has allowed it to build a strong brand reputation and expertise in the segment, making it a recognized name for health insurance.
Extensive Agent Network: It boasts one of the largest and most widespread agency networks in the Indian health insurance space, especially in Tier 2 and Tier 3 cities, providing deep market penetration.
Proprietary Hospital Network & In-house Claims: A large network of empaneled hospitals and an in-house claims settlement process contribute to better cost control and potentially superior customer experience compared to third-party administrators.
Scale: As a leader in retail health, it benefits from economies of scale in underwriting, claims management, and distribution.
Growth Drivers
Under-penetration of Health Insurance: India has very low health insurance penetration compared to developed economies, presenting a large untapped market.
Rising Healthcare Costs: Increasing medical inflation and a greater prevalence of lifestyle diseases are driving the need for health insurance.
Growing Health Awareness: The COVID-19 pandemic significantly boosted health insurance awareness and adoption.
Digital Adoption: Increasing digitalization and online sales channels can expand reach and improve operational efficiency.
Increasing Disposable Income: Rising income levels are allowing more individuals and families to afford health insurance.
Government Initiatives: Schemes like Ayushman Bharat are increasing overall health awareness and setting a baseline for health coverage.
Risks
Intense Competition: The entry of new players and aggressive strategies by existing general insurers can lead to pricing pressure and market share erosion.
Medical Inflation: Higher-than-expected medical inflation can significantly impact claims costs and underwriting profitability.
Regulatory Changes: Changes in IRDAI (Insurance Regulatory and Development Authority of India) regulations regarding product pricing, solvency margins, or distribution can impact operations and profitability.
Adverse Claims Experience: A sudden increase in claims frequency or severity (e.g., due to pandemics or new diseases) can severely affect financial performance.
Agent Attrition: Reliance on a large agent network means high agent attrition could impact distribution capability.
Investment Market Volatility: As insurers invest policyholder funds, adverse movements in financial markets can impact investment income.
Management & Ownership
Star Health was initially promoted by Safecrop Investments Ltd. (a consortium led by Westbridge Capital and Madison India Capital) along with other private equity investors and individual founders. Post-IPO, the ownership is diversified with significant stakes held by institutional investors (both domestic and foreign) and public shareholders. The management team comprises experienced professionals from the insurance and financial services sectors, overseeing operations and strategic direction.
Outlook
Star Health is well-positioned to capitalize on the significant growth potential in the Indian health insurance market, driven by its specialized focus, strong brand, and extensive distribution network, particularly in the retail segment. The long-term trajectory for health insurance penetration in India remains positive. However, the company faces intense competition from general insurers and other standalone health insurers, along with the constant challenge of managing medical inflation and maintaining underwriting profitability. Its ability to innovate products, expand its reach efficiently, and control claims costs will be crucial for sustained market leadership and profitable growth amidst a dynamic regulatory and competitive landscape.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 3294 | 3395 | 3520 | 3704 | 3800 | 3798 | 3938 | 4081 | 4250 | 4327 |
| Other Income | 285 | 296 | 297 | 357 | 348 | 290 | 296 | 300 | 318 | 325 |
| Total Income | 3579 | 3692 | 3817 | 4061 | 4148 | 4088 | 4234 | 4381 | 4568 | 4652 |
| Total Expenditure | 3191 | 3502 | 3391 | 3912 | 3861 | 4089 | 3882 | 4303 | 4395 | 4500 |
| Operating Profit | 388 | 190 | 426 | 149 | 287 | -1 | 352 | 78 | 173 | 151 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 388 | 190 | 426 | 149 | 287 | -1 | 352 | 78 | 173 | 151 |
| Provision for Tax | 98 | 47 | 107 | 38 | 72 | -1 | 90 | 23 | 45 | 40 |
| Profit After Tax | 290 | 142 | 319 | 111 | 215 | 1 | 263 | 55 | 128 | 111 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 290 | 142 | 319 | 111 | 215 | 1 | 263 | 55 | 128 | 111 |
| Adjusted Earnings Per Share | 4.9 | 2.4 | 5.4 | 1.9 | 3.7 | 0 | 4.5 | 0.9 | 2.2 | 1.9 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 1018 | 1514 | 1911 | 2740 | 3662 | 4684 | 4627 | 9809 | 11262 | 12938 | 14822 | 16596 |
| Other Income | 42 | 63 | 62 | 89 | 115 | 170 | 251 | 480 | 501 | 642 | 772 | 1239 |
| Total Income | 1060 | 1577 | 1974 | 2828 | 3778 | 4854 | 4877 | 10289 | 11763 | 13580 | 15594 | 17835 |
| Total Expenditure | 1207 | 1329 | 1877 | 2690 | 3548 | 4523 | 6358 | 11871 | 11057 | 12849 | 15201 | 17080 |
| Operating Profit | -147 | 249 | 97 | 138 | 229 | 330 | -1481 | -1582 | 706 | 731 | 393 | 754 |
| Interest | 1 | 2 | 3 | 7 | 2 | 3 | 3 | 26 | 35 | 39 | 24 | 0 |
| Depreciation | 19 | 17 | 20 | 23 | 28 | 29 | 46 | 43 | 52 | 59 | 71 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -140 | 137 | 118 | 171 | 267 | 406 | -1446 | -1397 | 826 | 1129 | 861 | 754 |
| Provision for Tax | 0 | 0 | 0 | 1 | 84 | 143 | -360 | -356 | 208 | 284 | 215 | 198 |
| Profit After Tax | -140 | 137 | 118 | 170 | 183 | 263 | -1086 | -1041 | 619 | 845 | 646 | 557 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -140 | 137 | 118 | 170 | 183 | 263 | -1086 | -1041 | 619 | 845 | 646 | 557 |
| Adjusted Earnings Per Share | -3.9 | 3.5 | 2.6 | 3.7 | 4 | 5.4 | -19.8 | -18.1 | 10.6 | 14.4 | 11 | 9.5 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 15% | 15% | 26% | 31% |
| Operating Profit CAGR | -46% | 0% | 4% | 0% |
| PAT CAGR | -24% | 0% | 20% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 12% | -1% | NA% | NA% |
| ROE Average | 10% | 12% | -6% | 1% |
| ROCE Average | 12% | 15% | -7% | 1% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 142 | 360 | 789 | 960 | 1493 | 1904 | 3500 | 4604 | 5434 | 6342 | 7024 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 250 | 250 | 250 | 250 | 720 | 470 | 470 | 470 |
| Other Non-Current Liabilities | 751 | 792 | 1190 | 1683 | 2158 | 2623 | 5187 | 6229 | 7292 | 8478 | 9170 |
| Total Current Liabilities | 210 | 238 | 278 | 537 | 914 | 1216 | 1564 | 1961 | 2030 | 2478 | 4121 |
| Total Liabilities | 1102 | 1390 | 2257 | 3430 | 4815 | 5994 | 10501 | 13514 | 15226 | 17768 | 20785 |
| Fixed Assets | 46 | 62 | 77 | 92 | 85 | 90 | 80 | 113 | 101 | 159 | 161 |
| Other Non-Current Assets | 514 | 810 | 1435 | 2169 | 3043 | 4309 | 7277 | 12154 | 13971 | 15866 | 18274 |
| Total Current Assets | 542 | 518 | 745 | 1169 | 1687 | 1595 | 3144 | 1247 | 1154 | 1744 | 2350 |
| Total Assets | 1102 | 1390 | 2257 | 3430 | 4815 | 5994 | 10501 | 13514 | 15226 | 17768 | 20785 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 57 | 80 | 94 | 229 | 372 | 750 | 513 | 1599 | 378 | 288 | 445 |
| Cash Flow from Operating Activities | 147 | 126 | 321 | 557 | 776 | 647 | 890 | 56 | 1276 | 1310 | 1379 |
| Cash Flow from Investing Activities | -216 | -192 | -497 | -663 | -731 | -1006 | -2418 | -3786 | -1097 | -1177 | -1151 |
| Cash Flow from Financing Activities | 92 | 81 | 310 | 249 | 333 | 122 | 2613 | 2509 | -268 | 23 | -4 |
| Net Cash Inflow / Outflow | 24 | 14 | 134 | 143 | 379 | -237 | 1086 | -1221 | -89 | 156 | 224 |
| Closing Cash & Cash Equivalent | 80 | 94 | 229 | 372 | 750 | 513 | 1599 | 378 | 288 | 445 | 668 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0 | 0 | 0 | 0 | 0 | 0 | -19.81 | -18.08 | 10.63 | 14.44 | 10.99 |
| CEPS(Rs) | -3.87 | 3.53 | 2.59 | 3.73 | 4.03 | 5.37 | -19.81 | -18.08 | 10.63 | 14.44 | 10.99 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 63.85 | 78.68 | 93.35 | 108.31 | 119.46 |
| Core EBITDA Margin(%) | -18.6 | 12.23 | 1.78 | 1.81 | 3.11 | 3.43 | -37.43 | -21.02 | 1.82 | 0.69 | -2.55 |
| EBIT Margin(%) | -13.76 | 9.02 | 6.17 | 6.25 | 7.29 | 8.67 | -31.25 | -14.24 | 7.34 | 8.72 | 5.81 |
| Pre Tax Margin(%) | -13.76 | 9.02 | 6.17 | 6.25 | 7.29 | 8.67 | -31.25 | -14.24 | 7.34 | 8.72 | 5.81 |
| PAT Margin (%) | -13.76 | 9.02 | 6.17 | 6.21 | 5.01 | 5.62 | -23.47 | -10.61 | 5.49 | 6.53 | 4.36 |
| Cash Profit Margin (%) | -13.76 | 9.02 | 6.17 | 6.21 | 5.01 | 5.62 | -23.47 | -10.61 | 5.49 | 6.53 | 4.36 |
| ROA(%) | -84.51 | 54.42 | 20.52 | 17.02 | 12.42 | 13.5 | -36.81 | -22.89 | 10.97 | 13.16 | 8.91 |
| ROE(%) | -84.51 | 54.42 | 20.52 | 19.46 | 17.45 | 17.28 | -40.19 | -25.93 | 12.42 | 14.36 | 9.67 |
| ROCE(%) | -84.51 | 54.42 | 20.52 | 17.13 | 20.52 | 22.91 | -48.98 | -31.04 | 14.83 | 17.76 | 12.04 |
| Receivable days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Payable days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 48.76 | 37.62 | 32.42 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9.03 | 5.55 | 5.01 | 2.98 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.03 | 0.08 | 0.07 | -0.02 | -0.12 | -0.03 | -0.29 | 4.19 | 2.69 | 2.46 | 1.4 |
| EV/Core EBITDA(x) | -0.23 | 0.46 | 1.29 | -0.34 | -1.91 | -0.37 | 0.9 | -25.95 | 42.95 | 43.5 | 52.73 |
| Net Sales Growth(%) | 50.72 | 48.72 | 26.26 | 43.33 | 33.68 | 27.9 | -1.23 | 112.02 | 14.81 | 14.89 | 14.56 |
| EBIT Growth(%) | -50.07 | 197.52 | -13.64 | 45.16 | 56 | 52.09 | -455.93 | 3.4 | 159.17 | 36.6 | -23.72 |
| PAT Growth(%) | -50.07 | 197.52 | -13.64 | 44.27 | 7.79 | 43.56 | -512.34 | 4.15 | 159.44 | 36.6 | -23.57 |
| EPS Growth(%) | 0 | 0 | 0 | 0 | 0 | 0 | -469.12 | 8.72 | 158.81 | 35.76 | -23.89 |
| Debt/Equity(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.16 | 0.09 | 0.07 | 0.07 |
| Current Ratio(x) | 0.56 | 0.5 | 0.51 | 0.53 | 0.54 | 0.42 | 0.47 | 0.15 | 0.12 | 0.16 | 0.18 |
| Quick Ratio(x) | 0.56 | 0.5 | 0.51 | 0.53 | 0.54 | 0.42 | 0.47 | 0.15 | 0.12 | 0.16 | 0.18 |
| Interest Cover(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.02 | 0.02 | 0.01 | 0.02 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 57.94 | 57.92 | 57.9 | 57.69 | 57.68 | 57.67 | 58.04 | 58.02 | 57.98 | 57.98 |
| FII | 31 | 26.57 | 21.58 | 17.65 | 17.51 | 18.68 | 13.9 | 13.5 | 14.07 | 15.05 |
| DII | 6.11 | 11.14 | 15.11 | 17.05 | 16.43 | 15.43 | 21.08 | 21.09 | 20.96 | 20.3 |
| Public | 4.96 | 4.36 | 5.41 | 7.61 | 8.38 | 8.21 | 6.98 | 7.39 | 6.99 | 6.66 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 33.9 | 33.9 | 33.9 | 33.9 | 33.9 | 33.9 | 34.12 | 34.12 | 34.12 | 34.12 |
| FII | 18.14 | 15.55 | 12.64 | 10.37 | 10.29 | 10.98 | 8.17 | 7.94 | 8.28 | 8.86 |
| DII | 3.57 | 6.52 | 8.85 | 10.02 | 9.65 | 9.07 | 12.39 | 12.4 | 12.33 | 11.95 |
| Public | 2.9 | 2.55 | 3.17 | 4.47 | 4.92 | 4.83 | 4.1 | 4.34 | 4.11 | 3.92 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 58.51 | 58.53 | 58.55 | 58.76 | 58.77 | 58.78 | 58.78 | 58.79 | 58.84 | 58.84 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +15% | +15% | +26% | +31% |
| Operating Profit CAGR | -46% | — | +4% | — |
| PAT CAGR | -24% | — | +20% | — |
| Share Price CAGR | +12% | -1% | — | — |
| ROE Average | +10% | +12% | -6% | +1% |
| ROCE Average | +12% | +15% | -7% | +1% |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 57.94 | 57.92 | 57.9 | 57.69 | 57.68 | 57.67 | 58.04 | 58.02 | 57.98 | 57.98 |
| FII | 31 | 26.57 | 21.58 | 17.65 | 17.51 | 18.68 | 13.9 | 13.5 | 14.07 | 15.05 |
| DII | 6.11 | 11.14 | 15.11 | 17.05 | 16.43 | 15.43 | 21.08 | 21.09 | 20.96 | 20.3 |
| Public | 42.06 | 42.08 | 42.1 | 42.31 | 42.32 | 42.33 | 41.96 | 41.98 | 42.02 | 42.02 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 33.9 | 33.9 | 33.9 | 33.9 | 33.9 | 33.9 | 34.12 | 34.12 | 34.12 | 34.12 |
| FII | 18.14 | 15.55 | 12.64 | 10.37 | 10.29 | 10.98 | 8.17 | 7.94 | 8.28 | 8.86 |
| DII | 3.57 | 6.52 | 8.85 | 10.02 | 9.65 | 9.07 | 12.39 | 12.4 | 12.33 | 11.95 |
| Public | 24.61 | 24.63 | 24.65 | 24.86 | 24.87 | 24.88 | 24.67 | 24.68 | 24.72 | 24.73 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 58.51 | 58.53 | 58.55 | 58.76 | 58.77 | 58.78 | 58.78 | 58.79 | 58.84 | 58.84 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.